Notice Information
Notice Title
Purchase of DPYD (dihydropyrimidine dehydrogenase) testing kits
Notice Description
All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient. Due to considerable increase in the demand for the test the AWMGL intends to award a two year contract (for a period of 12 months with the option to extend for a further 12 months) to ensure continuity of service to the patients of NHS Wales.
Lot Information
Lot 1
All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient. The test has continued to grow in demand across Wales for an established DPYD service and as a consequence AWMGL is now required to advertise their intention award a contract to Yourgene Health UK without prior advertisement. The Elucigene DPYD assay provided by Yourgene Health UK Limited is deemed the only technology suitable for meeting the lab requirements for the following reasons; The test has already been validated by the laboratory as it has been used for a number of years, therefore meets the standards required to deliver the service. A change in technology or provider would require a considerable validation process which would have considerable cost and time implications to the laboratory and would be extremely detrimental to patient care. The technology used for the test is also used for other services provided by the AWMGL. This further provides evidence that the technology is already suitable for use and also allows streamlining of in house testing. The equipment needed for the test is already in place. Change in technology may incur considerable extra costs from requirement to purchase and maintain new equipment. Elucigene DPYD assay is IVD marked; thereby future-proofing the test for any future requirements for the lab to use IVD approved technologies for this test. Test was cost assessed by the department at the point of validation and has been deemed the most cost effective method of testing (taking into consideration all the points above) NWSSP Procurement Services intends to award a contract on behalf of Cardiff and Vale University Health Board, AWMGL, for the supply of a The Elucigene DPYD assay provided by Yourgene Health UK Limited, for the unique reasons outlined above. The contract is estimated to commence in July 2021, for a period of two years (to be awarded for 12 months with the option to extend for a further 12 months) for estimated quantity of 144 kits (3600 samples) per annum. The contract will include all associated services.
Procurement Information
All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient. The Elucigene DPYD assay provided by Yourgene Health UK Limited is deemed the only technology suitable for meeting the lab requirements for the following reasons; The test has already been validated in the lab and is confirmed as being suitable for use. A change in technology or provider would require a considerable validation process which would have considerable cost and time implications to the lab and be extremely detrimental to patient care. The technology used for the test is also used for other services provided by the AWMGL. This further provides evidence that the technology is already suitable for use and also allows streamlining of in house testing. The equipment needed for the test is already in place and maintained. Change in technology may incur considerable extra costs from requirement to purchase and maintain new equipment. Elucigene DPYD assay is IVD marked; thereby future-proofing the test for any future requirements for the lab to use IVD approved technologies for this test. Test was cost assessed by the department at the point of validation and has been deemed the most cost effective method of testing (taking into consideration all the points above)
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-02bcb3
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/013632-2021
- Current Stage
- Award
- All Stages
- Award
Procurement Classification
- Notice Type
- Award Notice
- Procurement Type
- Standard
- Procurement Category
- Goods
- Procurement Method
- Limited
- Procurement Method Details
- Award procedure without prior publication of a call for competition
- Tender Suitability
- Not specified
- Awardee Scale
- Large
Common Procurement Vocabulary (CPV)
- CPV Divisions
33 - Medical equipments, pharmaceuticals and personal care products
-
- CPV Codes
33696500 - Laboratory reagents
Notice Value(s)
- Tender Value
- Not specified
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- £232,200 £100K-£500K
Notice Dates
- Publication Date
- 16 Jun 20214 years ago
- Submission Deadline
- Not specified
- Future Notice Date
- Not specified
- Award Date
- 31 May 20214 years ago
- Contract Period
- Not specified - Not specified
- Recurrence
- Not specified
Notice Status
- Tender Status
- Complete
- Lots Status
- Not Specified
- Awards Status
- Active
- Contracts Status
- Active
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- NHS WALES SHARED SERVICES PARTNERSHIP-PROCUREMENT SERVICES (HOSTED BY VELINDRE UNIVERSITY NHS TRUST)
- Contact Name
- Ryan James
- Contact Email
- ryan.james3@wales.nhs.uk
- Contact Phone
- +44 2921836442
Buyer Location
- Locality
- CARDIFF
- Postcode
- CF14 4TT
- Post Town
- Cardiff
- Country
- Wales
-
- Major Region (ITL 1)
- TLL Wales
- Basic Region (ITL 2)
- TLL5 South East Wales
- Small Region (ITL 3)
- TLL52 Cardiff and Vale of Glamorgan
- Delivery Location
- TLL22 Cardiff and Vale of Glamorgan
-
- Local Authority
- Cardiff
- Electoral Ward
- Heath
- Westminster Constituency
- Cardiff North
Further Information
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-02bcb3-2021-06-16T14:54:02+01:00",
"date": "2021-06-16T14:54:02+01:00",
"ocid": "ocds-h6vhtk-02bcb3",
"description": "NOTE: To register your interest in this notice and obtain any additional information please visit the Sell2Wales Web Site at https://www.sell2wales.gov.wales/Search/Search_Switch.aspx?ID=111498. (WA Ref:111498)",
"initiationType": "tender",
"tender": {
"id": "CAV-STA (2021/2022) 9",
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"title": "Purchase of DPYD (dihydropyrimidine dehydrogenase) testing kits",
"status": "complete",
"classification": {
"scheme": "CPV",
"id": "33696500",
"description": "Laboratory reagents"
},
"mainProcurementCategory": "goods",
"description": "All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient. Due to considerable increase in the demand for the test the AWMGL intends to award a two year contract (for a period of 12 months with the option to extend for a further 12 months) to ensure continuity of service to the patients of NHS Wales.",
"lots": [
{
"id": "1",
"description": "All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient. The test has continued to grow in demand across Wales for an established DPYD service and as a consequence AWMGL is now required to advertise their intention award a contract to Yourgene Health UK without prior advertisement. The Elucigene DPYD assay provided by Yourgene Health UK Limited is deemed the only technology suitable for meeting the lab requirements for the following reasons; The test has already been validated by the laboratory as it has been used for a number of years, therefore meets the standards required to deliver the service. A change in technology or provider would require a considerable validation process which would have considerable cost and time implications to the laboratory and would be extremely detrimental to patient care. The technology used for the test is also used for other services provided by the AWMGL. This further provides evidence that the technology is already suitable for use and also allows streamlining of in house testing. The equipment needed for the test is already in place. Change in technology may incur considerable extra costs from requirement to purchase and maintain new equipment. Elucigene DPYD assay is IVD marked; thereby future-proofing the test for any future requirements for the lab to use IVD approved technologies for this test. Test was cost assessed by the department at the point of validation and has been deemed the most cost effective method of testing (taking into consideration all the points above) NWSSP Procurement Services intends to award a contract on behalf of Cardiff and Vale University Health Board, AWMGL, for the supply of a The Elucigene DPYD assay provided by Yourgene Health UK Limited, for the unique reasons outlined above. The contract is estimated to commence in July 2021, for a period of two years (to be awarded for 12 months with the option to extend for a further 12 months) for estimated quantity of 144 kits (3600 samples) per annum. The contract will include all associated services.",
"hasOptions": false
}
],
"items": [
{
"id": "1",
"deliveryAddresses": [
{
"region": "UKL22"
}
],
"deliveryLocation": {
"description": "All Wales Medical Genomics Service, Institute of Medical Genetics, University Hospital of Wales, Heath Park, Cardiff, CF14 4XW"
},
"relatedLot": "1"
}
],
"procurementMethod": "limited",
"procurementMethodDetails": "Award procedure without prior publication of a call for competition",
"coveredBy": [
"GPA"
],
"reviewDetails": "The Authority will allow a minimum 10 calendar day standstill period between notifying the award decision and awarding the contract. Should additional information be required from the addressee in section 1.1 Ryan James (ryan.james3@wales.nhs.uk). The Contracting Authority will enter into this Contract following a minimum 10 day calendar day standstill period starting on the day after this notice is published on Find a Tender. If legal proceedings are commenced in relation to the contract award, it will be necessary to suspend the award of the contract pending further order of the Court, or the authority may voluntarily decide (at its discretion) to suspend the award of contract whilst any outstanding queries are dealt with. We will not be liable for any costs or losses incurred by you as a result of any suspension of the contract award or as a result of any other action made necessary by any challenge.",
"procurementMethodRationaleClassifications": [
{
"scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
"id": "D_OUTSIDE_SCOPE",
"description": "The procurement falls outside the scope of application of the directive"
}
],
"procurementMethodRationale": "All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient. The Elucigene DPYD assay provided by Yourgene Health UK Limited is deemed the only technology suitable for meeting the lab requirements for the following reasons; The test has already been validated in the lab and is confirmed as being suitable for use. A change in technology or provider would require a considerable validation process which would have considerable cost and time implications to the lab and be extremely detrimental to patient care. The technology used for the test is also used for other services provided by the AWMGL. This further provides evidence that the technology is already suitable for use and also allows streamlining of in house testing. The equipment needed for the test is already in place and maintained. Change in technology may incur considerable extra costs from requirement to purchase and maintain new equipment. Elucigene DPYD assay is IVD marked; thereby future-proofing the test for any future requirements for the lab to use IVD approved technologies for this test. Test was cost assessed by the department at the point of validation and has been deemed the most cost effective method of testing (taking into consideration all the points above)"
},
"awards": [
{
"id": "013632-2021-CAV-STA (2021/2022) 9-1",
"relatedLots": [
"1"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-19699",
"name": "Yourgene Health"
}
]
}
],
"parties": [
{
"id": "GB-FTS-19698",
"name": "NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)",
"identifier": {
"legalName": "NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)"
},
"address": {
"streetAddress": "2nd Floor Woodland House",
"locality": "Cardiff",
"region": "UK",
"postalCode": "CF144TT",
"countryName": "United Kingdom"
},
"contactPoint": {
"name": "Ryan James",
"telephone": "+44 2921836442",
"email": "ryan.james3@wales.nhs.uk"
},
"roles": [
"buyer"
],
"details": {
"url": "http://nwssp.nhs.wales/ourservices/procurement-services/",
"buyerProfile": "https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0221",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"id": "BODY_PUBLIC",
"description": "Body governed by public law"
},
{
"scheme": "COFOG",
"id": "07",
"description": "Health"
}
]
}
},
{
"id": "GB-FTS-19699",
"name": "Yourgene Health",
"identifier": {
"legalName": "Yourgene Health"
},
"address": {
"streetAddress": "Nelson Street",
"locality": "Manchester",
"region": "UKD33",
"postalCode": "M139NQ",
"countryName": "United Kingdom"
},
"contactPoint": {
"telephone": "+44 7584917415"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-111",
"name": "High Court",
"identifier": {
"legalName": "High Court"
},
"address": {
"streetAddress": "Royal Courts of Justice, The Strand",
"locality": "London",
"postalCode": "WC2A 2LL",
"countryName": "United Kingdom"
},
"contactPoint": {
"telephone": "+44 2079477501"
},
"roles": [
"reviewBody"
]
}
],
"buyer": {
"id": "GB-FTS-19698",
"name": "NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)"
},
"contracts": [
{
"id": "013632-2021-CAV-STA (2021/2022) 9-1",
"awardID": "013632-2021-CAV-STA (2021/2022) 9-1",
"status": "active",
"value": {
"amount": 232200,
"currency": "GBP"
},
"dateSigned": "2021-06-01T00:00:00+01:00"
}
],
"language": "en"
}